Advancing a class on top of statins
Investors & Media

2018 Press Releases

Keyword Search
 
2018 | 2017 | 2016
DateTitle  
08/13/18Gemphire Therapeutics Reports Second Quarter 2018 Financial Results and Provides Corporate Update
LIVONIA, Mich., Aug. 13, 2018 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ: GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, including dyslipidemia and nonalcoholic steatohepatitis (NASH), today announced financial results for the quarter and six months ended June 30, 2018, and provided a corporate update. “We capped off our second quarter by announcing that our INDIGO-1 trial investigating gemcabe... 
Download PDFPrinter Friendly Version
08/10/18Gemphire Announces Termination of Phase 2a Clinical Trial of Gemcabene in Pediatric NAFLD
LIVONIA, Mich., Aug. 10, 2018 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ: GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, including dyslipidemia and nonalcoholic steatohepatitis (NASH), announces today that the Data and Safety Monitoring Board (DSMB) at Emory University School of Medicine overseeing the investigator-led open label Phase 2a proof-of-concept trial evaluating gemcabene in pediatric pa... 
Download PDFPrinter Friendly Version
08/06/18Gemphire Provides Update On Development of Gemcabene
FDA requests the Company provide additional data regarding the partial clinical hold Company continues Phase 2 development of gemcabene for NAFLD/NASH Company amends loan agreement with SVB to provide additional flexibility Conference call and webcast today, Monday, August 6, at 4:30 p.m. Eastern Time LIVONIA, Mich., Aug. 06, 2018 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ: GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies f... 
 Printer Friendly Version
08/06/18Gemphire Announces Amended and Restated Gemcabene License Agreement with Pfizer Inc.
LIVONIA, Mich., Aug. 06, 2018 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ: GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, including dyslipidemia and nonalcoholic steatohepatitis (NASH), today announced that it has amended and restated the license agreement with Pfizer Inc. covering gemcabene.Gemphire licensed exclusive worldwide commercial rights to gemcabene from Pfizer in an agreement signed in Apr... 
Download PDFPrinter Friendly Version
06/28/18Gemcabene Meets Primary Endpoint in INDIGO-1 Study of Severe Hypertriglyceridemia (SHTG) Patients
Gemcabene demonstrated statistically significant lowering of triglycerides (TGs) in SHTG Secondary endpoints achieved included statistically significant reductions in serum LDL-C, non-HDL-C, VLDL-C, apoB, apoE, apoCIII, and SAA Gemcabene showed evidence of safety and tolerability in combination with statins INDIGO-1 results further support Gemphire’s rationale for developing gemcabene as a treatment for NAFLD/NASH Conference call and webcast today, Thursday, June 28, at 4:30 p.m. Eastern T... 
 Printer Friendly Version
05/18/18Gemphire Therapeutics Provides the American Liver Foundation an Educational Grant in Support of Disease State Awareness for Pediatric NAFLD
LIVONIA, Mich., May 17, 2018 -- Gemphire Therapeutics Inc. (NASDAQ: GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, including non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH) and dyslipidemia, has provided an educational grant to the American Liver Foundation (ALF) to support an upcoming webinar titled "Pediatric Non-Alcoholic Fatty Liver Disease—Yes, It A... 
Download PDFPrinter Friendly Version
05/08/18Gemphire Therapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update
LIVONIA, Mich., May 08, 2018 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, including non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH) and dyslipidemia, today announced financial results for the first quarter ended March 31, 2018, and provided a corporate update. “Gemphire had a strong start to 2018 with continued progress... 
Download PDFPrinter Friendly Version
05/03/18Gemphire Therapeutics Announces the Appointment of Steven Gullans, Ph.D., as President and Chief Executive Officer
LIVONIA, Mich., May 03, 2018 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, including dyslipidemia and Nonalcoholic Steatohepatitis (NASH), today announced the appointment of Steven Gullans, Ph.D., as its President and Chief Executive Officer, effective immediately. Dr. Gullans has been Interim President and Chief Executive Officer since May 2017.  He has... 
Download PDFPrinter Friendly Version
04/12/18Gemphire Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(C)(4)
LIVONIA, Mich., April 12, 2018 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, including dyslipidemia and Nonalcoholic Steatohepatitis (NASH), today announced that on April 9, 2018, the Compensation Committee of its Board of Directors, which is composed entirely of independent directors, approved an equity award under Gemphire’s Inducement Plan, as a mater... 
Download PDFPrinter Friendly Version
03/15/18Gemphire Therapeutics Reports Fourth Quarter and Fiscal Year 2017 Financial Results
Conference Call & Live Webcast Today at 4:30pm Eastern Time LIVONIA, Mich., March 15, 2018 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, including dyslipidemia, non-alcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), today announced its financial results for the quarter and fiscal year ended December 31, 2017, and provided a... 
Download PDFPrinter Friendly Version
03/13/18Gemphire Therapeutics to Announce Fourth Quarter and Year End 2017 Financial Results on Thursday, March 15
LIVONIA, Mich., March 13, 2018 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, including dyslipidemia, non-alcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), today announced that it will host a conference call and live audio webcast on Thursday, March 15, 2018 at 4:30 p.m. Eastern Time to discuss financial results for the fourth... 
Download PDFPrinter Friendly Version
03/08/18Gemphire to Present at Two Investor Conferences
LIVONIA, Mich., March 08, 2018 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, including dyslipidemia, non-alcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), today announced that management will be making presentations at the 30th Annual ROTH Conference and the H.C. Wainwright 2nd Annual NASH Investor Conference. Pr... 
Download PDFPrinter Friendly Version
02/27/18Gemphire Expert Panel Call on Pediatric Nonalcoholic Fatty Liver Disease (NAFLD) and NASH to be Rescheduled
LIVONIA, Mich., Feb. 27, 2018 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, including dyslipidemia, non-alcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), today announced that due to a family emergency of one of the a panel members, it will need to reschedule the expert panel call discussing pediatric nonalcoholic fatty liver ... 
Download PDFPrinter Friendly Version
02/21/18Gemphire to Host Expert Panel Call to Discuss Pediatric Nonalcoholic Fatty Liver Disease (NAFLD) and NASH
Conference Call and Live Webcast on February 28 at 12:00pm EST LIVONIA, Mich., Feb. 21, 2018 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, including dyslipidemia, non-alcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), will host an expert panel call and live webcast to discuss pediatric NAFLD on Wednesday, February 28 at 12:00... 
Download PDFPrinter Friendly Version
02/08/18Gemphire Announces Pricing of $22 Million Public Offering of Common Stock
LIVONIA, Mich., Feb. 08, 2018 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, including dyslipidemia, Non Alcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH), today announced the pricing of its previously announced underwritten public offering of 3,142,858 shares of its common stock at a public offering price of $7.00 per share. A... 
Download PDFPrinter Friendly Version
02/07/18Gemphire Announces Proposed Public Offering of Common Stock
LIVONIA, Mich., Feb. 07, 2018 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, including dyslipidemia, Non Alcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH), announced today that it has commenced an underwritten public offering of its common stock.  All shares of common stock to be sold in the offering will be offered by Gemphire... 
Download PDFPrinter Friendly Version
01/31/18Gemphire Announces Initiation of Phase 2a Clinical Trial of Gemcabene in Pediatric Non-Alcoholic Fatty Liver Disease (NAFLD)
Pediatric NAFLD/NASH is a large and untreated market; provides an opportunity to advance gemcabene in an underserved area with millions of affected patients Proof-of-concept clinical trial expands company’s differentiated NAFLD/NASH program across both adults and adolescents US Patent No. US 9,849,104, “Treatment of NASH with Gemcabene” issued, further enhancing intellectual property protection Company to host conference call and live webcast at 4:30 pm ET today LIVONIA, Mich., Jan. 31, 201... 
Download PDFPrinter Friendly Version
01/17/18Gemphire Completes Patient Enrollment in INDIGO-1 Trial in Severe Hypertriglyceridemia (SHTG) Patients
On Track to Report Top-Line Data from Phase 2b Trial in Second Quarter of 2018 LIVONIA, Mich., Jan. 17, 2018 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, including dyslipidemia and nonalcoholic steatohepatitis (NASH), today announced that it has achieved its enrollment goal of 90 subjects across 39 sites in its Phase 2b INDIGO-1 trial investigating g... 
Download PDFPrinter Friendly Version